ArticleExperimental and therapeutic medicine2026
Changes in iron metabolism after primary PCI in patients with STEMI and ischemia-reperfusion injury.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Within the present study, the aim was to investigate the dynamic changes in iron metabolism parameters in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) and to evaluate their association with the occurrence of ischemia-reperfusion injury (IRI). The present single-center, prospective observational study enrolled 68 patients with STEMI undergoing primary PCI from January to December 2024. Clinical characteristics, laboratory data and echocardiographic findings were collected. Patients were classified into IRI (n=30) and non-IRI (n=38) groups based on predefined IRI criteria. Venous blood samples were obtained pre- and post-PCI to measure ferritin, hepcidin, heme and heme oxygenase-1 (HO-1) levels. Statistical analyses were conducted to compare the changes in these iron metabolism indices between the two groups. Among the 68 enrolled patients, the incidence of IRI was 44.1%. Ferritin showed a significant increase post-PCI. The rise in ferritin and hepcidin was more pronounced in the IRI group compared with the non-IRI group. Although both IRI and non-IRI groups exhibited an upward trend in heme and HO-1 after PCI, the elevation in heme was higher in the IRI group in comparison with the HO-1. Differences in heme and HO-1 between IRI and non-IRI groups were not statistically significant. In conclusion, post-PCI rises in ferritin and hepcidin were more pronounced in patients with STEMI and IRI, while heme and HO-1 showed non-significant upward trends. These results indicated an association between altered iron/heme metabolism and IRI and therefore support further evaluation of ferritin/hepcidin as candidate biomarkers, pending validation in larger multicenter studies with multivariable adjustment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.